SecBot SecBot
SECBOTREPLAY Home › Report › GANX

GANX · Q3 loss $0.07, cash $11.7M

Gain Therapeutics, Inc. · PRESS-RELEASE filed Nov 10, 2026 at 07:00 ET

At the news

NEUTRALIMPACT 4/10

PRESS-RELEASE filed Nov 10, 2026 at 07:00 ET

Gain Therapeutics reported Q3 2026 net loss of $0.07 per share, narrower than the $0.15 loss a year ago and better than the $-0.13 consensus. Cash burn continues with $11.7M on hand, and the company expects to start a Phase 2 trial of rexaceract in Q1 2027.

  • Net loss per share $0.07 for Q3 2026 vs $0.15 in Q3 2025
  • Cash and cash equivalents $11.7M as of Sep 30, 2026, down from $20.8M at Dec 31, 2025
  • Phase 2 trial of rexaceract expected to begin in Q1 2027
  • R&D expenses fell to $1.4M from $2.8M year-over-year

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access